Clinical Research Directory

Inclusion Criteria: 1. Stage Ⅲ，Ⅳ sarcoma patients or recurrent sarcoma patients; 2. Age: ≥ 18 and ≤65 years of age at the time of enrollment; 3. At least 4 weeks since any chemotherapy or radiotherapy and at least 1 week since immunosuppressive therapy such as using steroid hormone before enrollment; 4. Side effects of chemotherapy have been well managed; 5. Malignant cells are target antigen positive(higher than ++) confirmed by IHC, quantitative PCR or sequencing; 6. Karnofsky /jansky score of 50% or greater; 7. Expected survival \> 6 weeks; 8. ANC≥ 1×10\^6/L，PLT ≥ 1×10\^8/L; 9. Pulse oximetry of≥90% on room air； 10. Adequate hepatic function,defined as aspartate aminotransferase(AST)\< 5 times upper limit of normal(ULN),serum bilirubin \< 3 times ULN; 11. Adequate renal function,defined as serum creatinine less than 2 times ULN,if serum creatinine more than 1.5 times ULN,creatinine clearance rate test is needed; 12. Patients must have autologous transduced T cells at levels greater than 15%; 13. Sign an informed consent and assent. Exclusion Criteria: 1. The disease is progresseing rapidly; 2. The patient is receiving therapy of other new drugs; 3. Evidence of tumor potentially causing airway obstruction; 4. Epilepsy history or other CNS diseases; 5. Patients who need immunosuppressive drugs because of GVAD; 6. History of long QT syndrome or severe heart diseases; 7. Uncontrolled active infection; 8. Active hepatitis B virus,hepatitis C virus and HIV infection; 9. Receiving systemic corticosteroid 2 weeks before enrollment except for inhaled steroids; 10. Previous treatment with any gene therapy; 11. Creatinine\>2.5mg/dl or ALT/AST\>3 times normal or bilirubin\>2.0 mg/dl; 12. Patients who have other uncontrolled diseases would preclude participation as outlined; 13. Pregnant or lactating women; 14. Patients previously experienced toxicity from cyclophosphamide; 15. Patients who have CNS sarcoma; 16. In condition that may bring risks to subjects or interference to clinical trials.